The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Brain disease patients with a year to live could choose assisted dying under plans to be considered by MPs next week ...

MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

The world-renowned Israeli-Argentine pianist and conductor Daniel Barenboim revealed Thursday he is suffering from ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...